SCHEMBL4358668

SCHEMBL4358668

CC(C)CCNc1ncnc2ccc(-c3ccc(C(=O)c4ccccc4)cc3)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 17/20 0.57
CYP3A4 P08684 16/20 0.57
ALDH1A1 P00352 15/20 0.57
HSD17B10 Q99714 14/20 0.57
CLK4 Q9HAZ1 13/20 0.57
CYP2D6 P10635 11/20 0.57
USP2 O75604 11/20 0.57
CYP2C19 P33261 11/20 0.57
MAPK1 P28482 8/20 0.57
LMNA P02545 5/20 0.57
TSHR P16473 6/20 0.54
KDM4E B2RXH2 4/20 0.54
HPGD P15428 4/20 0.54
HIF1A Q16665 3/20 0.50
MAP4K4 O95819 1/20 0.49
CYP2C9 P11712 1/20 0.48
ALOX12 P18054 1/20 0.48
APEX1 P27695 1/20 0.48
CASP7 P55210 1/20 0.48
MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4353661 1.00 CYP1A2 (0.57) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4355900 0.89 MAP4K4 (0.60) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4353222 0.87 CYP1A2 (0.56) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4355285 0.84 RAF1 (0.54) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4359413 0.83 ALDH1A1 (0.56) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4362061 0.83 CYP1A2 (0.54) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4361101 0.82 CYP1A2 (0.62) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4356010 0.82 ALDH1A1 (0.54) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4363909 0.82 MAP4K4 (0.49) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4
SCHEMBL4355740 0.82 CYP1A2 (0.55) CYP1A2CYP3A4ALDH1A1HSD17B10CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US claimed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 US disclosed
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2021-01-05 US disclosed
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2016-09-08 US disclosed
US-9259426-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2016-02-16 US disclosed
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2009-11-19 US disclosed
WO-2008009078-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 CYP1A2 1131/4885CYP3A4 256/4885ALDH1A1 2743/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 CYP1A2 1131/4885CYP3A4 256/4885ALDH1A1 2743/4885
US-20090285782-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR5A2, NR4A1 CYP1A2 1129/4885CYP3A4 274/4885ALDH1A1 2942/4885
US-10882851-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR5A2 CYP1A2 1078/4885CYP3A4 271/4885ALDH1A1 3119/4885
US-20160257673-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR5A2 CYP1A2 1078/4885CYP3A4 271/4885ALDH1A1 3119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.